You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Integrated molecular diagnostic system for the point-of-care

    SBC: BIOHELIX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic vents to gate fluid movements through micro channels, and multiple reaction chambers for experimenta ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Isolation of functional IgGs in the cytoplasm of a novel E. coli expression host

    SBC: NEW ENGLAND BIOLABS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) hold great promise in human health with applications ranging from therapeutic agents that target cancer cells, to diagnostic biomarkers that can detect trace levels of a given antigen. Thispromise is best reflected in global sales of antibodies which reached nearly 31 billion in 2007 and future sales predicted to reach 56 billion ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical development of novel small molecule malaria drugs that overcome drug

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs th ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated catheters have been developed to combat these infections, however, many of them have limited clinical effica ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Developing small molecule therapeutics for lupus

    SBC: Biomedical Research Models, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) affects ~ 2 million Americans with devastating impact on multiple organs, especially the skin, joints, kidney, and brain. Therapeutic strategies for lupus are largely palliative orimmunosuppressive with serious toxicities. No new drugs for SLE have been approved in decades. Thus, novel therapeutic approaches to lupus - par ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. FAH-Deficient Pigs

    SBC: Yecuris Corporation            Topic: NIDDK

    DESCRIPTION (provided by applicant): Translational research in the field of liver disease has been limited by a shortage of large animal models, which in turn has limited development of new therapies for metabolic liver disorders, acute liver failure, chronic (cirrhotic) liver disease, an hepatocellular carcinoma. While new transgenic and knockout rodent models of liver disease have facilitated ba ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. High-throughput portable software for fragment-based drug design

    SBC: ACPHARIS            Topic: NIGMS

    DESCRIPTION (provided by applicant): Fragment-based drug design (FBDD) is a combinatorial approach in which individual fragments binding to regions of the target site are selected from a fragment library, and then combined to form potential lead compounds.Interest in this approach has significantly increased during the last few years, with many companies using FBDD methods based on X-ray crystallo ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity

    SBC: QUINTESSENCE CHEMICALS, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Overdose on acetaminophen (more commonly known by the brand name Tylenol(R)), accounts for 56,000 emergency room visits and more than 450 deaths annually in the USA. Acetaminophen overdose can occur by a single event ofexceeding the recommended daily dosage. Overdose on acetaminophen is facilitated by the fact that it is a common ingredient in over-the-counter ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Emergency Operations Plans for Individuals with Disabilities

    SBC: PRAXIS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The proposed project is designed to fill an important yet unmet need by developing an online training program that has the potential for reaching all emergency managers, responders and students in the field of emergencypreparedness with a specific focus on individuals with disabilities. Pursuing this objective, the applicant organization, Praxis, Inc., and the ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government